Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis

Lucy Thorne, Armando Arias, Ian Goodfellow

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.
Original languageEnglish
JournalJournal of Infectious Diseases
Volume213
Issue numbersuppl 1
Pages (from-to)27-31
ISSN0022-1899
DOIs
Publication statusPublished - 2016
Externally publishedYes

Cite this

Thorne, Lucy ; Arias, Armando ; Goodfellow, Ian. / Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis. In: Journal of Infectious Diseases. 2016 ; Vol. 213, No. suppl 1. pp. 27-31.
@article{81af28fd9cd64aa4b6d64cea813ffffc,
title = "Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis",
abstract = "Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.",
author = "Lucy Thorne and Armando Arias and Ian Goodfellow",
year = "2016",
doi = "10.1093/infdis/jiv280",
language = "English",
volume = "213",
pages = "27--31",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "suppl 1",

}

Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis. / Thorne, Lucy; Arias, Armando; Goodfellow, Ian.

In: Journal of Infectious Diseases, Vol. 213, No. suppl 1, 2016, p. 27-31.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis

AU - Thorne, Lucy

AU - Arias, Armando

AU - Goodfellow, Ian

PY - 2016

Y1 - 2016

N2 - Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.

AB - Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.

U2 - 10.1093/infdis/jiv280

DO - 10.1093/infdis/jiv280

M3 - Journal article

VL - 213

SP - 27

EP - 31

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - suppl 1

ER -